Pro and anti-inflammatory cytokines in patients with lung adenocarcinoma clinical stages IIIB and IV undergoing chemotherapy

Uriel Rumbo Nava (Mexico, Mexico), Uriel Rumbo Nava, José Sullivan López González, Lorenzo Islas Vázquez, Renata Alejandra Báez Saldaña

Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Session: Lung cancer and immune cells: friends or foes?
Session type: Poster Discussion
Number: 517
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Uriel Rumbo Nava (Mexico, Mexico), Uriel Rumbo Nava, José Sullivan López González, Lorenzo Islas Vázquez, Renata Alejandra Báez Saldaña. Pro and anti-inflammatory cytokines in patients with lung adenocarcinoma clinical stages IIIB and IV undergoing chemotherapy. Eur Respir J 2016; 48: Suppl. 60, 517

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Prognostic factors for stage IV lung adenocarcinoma patients receiving retreatment with EGFR-TKI
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015


Outcomes of radical treatment of early stage non-small cell lung cancer
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015


Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016

Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013

Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016

Procalcitonin serum levels in patients with stage IV non-small cell lung cancer in first line of chemotherapy
Source: International Congress 2016 – Clinical aspects of lung cancer
Year: 2016

Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016


A prospective study of survival after surgery for early stage non-small cell lung cancer in patients with COPD
Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery
Year: 2015



The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016

Comorbitities, responses and survival in pts with NSCLC
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014

A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016

Poor prognostic factors in advanced pulmonary adenocarcinoma patients receiving first-line gefitinib
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013

Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015

Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC)
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013


The impact of pulmonary rehabilitation on preoperative inflammatory markers in lung cancer patients
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013

Clinico-pathological prognostic factors for relapse in early stage non-small cell lung cancer after radical surgical resection
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013

Improved survival associated with neoadjuvant chemoradiation and surgery vs other means of treatment for NSCLC N2 patients (clinical stage IIIa and IIIb)
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015


Safety and efficacy of erlotinib in patients with squamous cell lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014

Advanced lung cancer inflammation index (ALI): A new pronostic score in patients with non small cell lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016


The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015